RMTI · Rockwell Medical, Inc.

0001628280-26-031663

Summary

Revenue was $17.3M (-8.3%) Gross Profit was $2.9M (-4.8%) Operating Income was -$1.5M (-8.8%) Net Income was -$1.6M (-5.9%)

Key takeaways

Gross profit of $2.9M decreased 4.8% but margin expanded slightly to 16.7% reflecting cost efficiencies amid product mix shifts.
Operating loss widened 8.8% to $1.5M as expense pressures offset sales and marketing reductions from lower headcount.
Net loss increased 5.9% to $1.6M with diluted EPS steady at -$0.04, consistent with prior year.

Full analysis

Gross profit was $2.9 million, a 4.8% decline from $3.0 million, yet the gross margin of 16.7% demonstrated resilience. This stability reflects effective cost management, including lower production headcount and overhead, despite the unfavorable DaVita mix shift which typically carries higher margins. No impairment losses were recorded related to prior plant closures, as assets were fully depreciated or transferred, supporting ongoing cost discipline.